Dean Clinic

Madison, Wisconsin 53717

0 studies enrolling now · 15 studies all time

What they study most

Asthma, Chronic Hepatitis C, Degenerative Lesion of Articular Cartilage of Knee, Hepatitis C, Hepatitis C Virus, Hepatitis C Virus Infection, Indolent Non-Hodgkin's Lymphoma, Non-Small Cell Lung Cancer, Osteochondritis Dissecans, Urinary Catheter Blockage and Encrustation

Studies at this site

• A Study in Participants With Asthma Initiating Treatment With Omalizumab (Xolair) — Completed
• Phase II Randomized Trial Comparing GA101 and Rituximab in Untreated Low Tumor Burden Indolent Non-Hodgkin's Lymphoma — Stopped early
• Study to Determine the Effectiveness and Safety of a Three Drug Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) Infected Patients Not Previously Treated With Currently Available Medications — Completed
• DeNovo NT Longitudinal Data Collection (LDC) Knee Study — Status unconfirmed
• Study of pegInterferon Alfa-2a, Ribavirin, and Daclatasvir (BMS-790052) With or Without BMS-650032 for Participants in Some Hepatitis C Virus Trials — Completed
• A Study Comparing Bevacizumab Therapy With or Without Erlotinib for First-Line Treatment of Non-Small Cell Lung Cancer (ATLAS) — Completed
• Efficacy Study of Auriclosene Irrigation Solution on Urinary Catheter Patency — Status unconfirmed
• UNITY 1: A Study of an Investigational Treatment Regimen of Daclatasvir (DCV) + Asunaprevir (ASV) + BMS-791325 in a Fixed Dose Combination (the DCV 3DAA (Direct Acting Antiviral) Regimen) for 12 Weeks for the Treatment of Chronic Hepatitis C Virus (HCV) Genotype 1 Infection in Non-cirrhotic Subjects — Completed
• Study of Daclatasvir (BMS-790052) Add-on to Standard of Care in Treatment- naïve Patients — Completed
• Study to Determine the Safety and Effectiveness of Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) in Patients Who Have Previously Not Received the Standard of Care — Completed
• Study of the Anti-HCV Drug (BMS-790052) Combined With Peginterferon and Ribavirin in Patients Who Failed Prior Treatment — Completed
• Study of BMS-650032 With Peginterferon Alfa-2a Plus Ribavirin — Completed
• UNITY 2: A Study of an Investigational Treatment Regimen of DCV+ASV+BMS-791325 in a Fixed Dose Combination (the DCV 3DAA (Direct Acting Antiviral) Regimen) With or Without RBV for 12 Weeks for the Treatment of Chronic Hepatitis C Virus(HCV)Genotype 1 Infection in Subjects With Compensated Cirrhosis — Completed
• Phase III Hallmark QUAD: ASV+DCV+Peg+Rib (Nulls/Partials) — Completed
• Phase III Hallmark DUAL: ASV+DCV (Nulls/Partials, Intolerants/Ineligibles. Naives) — Completed